On the contrary, data supporting a renal benefit by SGLT2 inhibition were provided from disease models like ischemia-reperfusion injury (Chang et al., 2016), unilateral ureteric obstruction (Abbas et al., 2018), protein-overload proteinuria (Cassis et al., 2018), Ang II-dependent hypertension (Castoldi et al., 2020), cyclosporine-A nephropathy (Castoldi et al., 2021), adenine nephropathy (Yamato et al., 2020) and salt-sensitive hypertension in uninephrectomized rats (Kim et al., 2019). This evidence concerns the gene SLC5A2 and kidney disorder.